| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 09/29/2023 |
8-K/A
| Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits Interact... |
| 08/25/2023 |
3
| ZAVRL FRANK (Director) has filed a Form 3 on CervoMed Inc. |
| 08/24/2023 |
3
| Sabbagh Marwan (Director) has filed a Form 3 on CervoMed Inc. |
| 08/23/2023 |
3
| Blackburn Kelly (VP, Clinical Development) has filed a Form 3 on CervoMed Inc. |
| 08/23/2023 |
3
| ALAM JOHN J (CEO and President) has filed a Form 3 on CervoMed Inc. |
| 08/23/2023 |
3
| Gregoire Sylvie (10% Owner) has filed a Form 3 on CervoMed Inc. |
| 08/23/2023 |
3
| Poulton Jeffrey V. (Director) has filed a Form 3 on CervoMed Inc. |
| 08/23/2023 |
3
| TANNER JOHN WILLIAM (CFO) has filed a Form 3 on CervoMed Inc. |
| 08/17/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Material Modifications to Rights of Security Holders, Changes in Registra... |
| 08/14/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 08/14/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
3
| DAVIDSON JILL (Director) has filed a Form 3 on Diffusion Pharmaceuticals Inc. |
| 08/09/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 08/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 08/03/2023 |
8-K
| Other Events Interactive Data |
| 08/03/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 08/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/31/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/13/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/11/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 07/05/2023 |
4
| LANCHONEY DIANA M (Director) has filed a Form 4 on Diffusion Pharmaceuticals Inc.|
Txns:
| Disposed/sold 85 shares
@ $0
Exercised 232 restricted stock units
@ $0 |
|
| 06/02/2023 |
4
| Hollingsworth Jane H (Director) has filed a Form 4 on Diffusion Pharmaceuticals Inc.|
Txns:
| Disposed/sold 68 shares
@ $0
Exercised 183 restricted stock units
@ $0 |
|
| 05/19/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/19/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Departure of Directors or Certain... |
| 05/15/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/15/2023 |
8-K
| Investor presentation |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
|